Fri Jun 20 01:30:00 UTC 2025: Here’s a summary and rewrite of the article as a news report, focusing on the Indian perspective:
**Summary:**
A groundbreaking study details a new, simplified method of CAR T-cell therapy that eliminates the need for external cell modification and chemotherapy. Researchers successfully delivered mRNA directly into the body to reprogram T-cells to fight cancer and autoimmune diseases in animal models. This “in-vivo” approach offers the potential to drastically reduce costs, increase accessibility, and minimize the risks associated with traditional CAR T-cell therapy, particularly relevant for countries like India with high disease burdens and limited infrastructure. While promising, further human trials are needed to confirm safety and efficacy. If successful, this advancement could revolutionize immunotherapy and make it more accessible to a wider range of patients in India and globally.
**News Article:**
**Simplified CAR T-Cell Therapy Offers Hope for Cancer and Autoimmune Patients in India**
**Bengaluru, June 20, 2025:** A new study published in *Science* is generating excitement among oncologists and immunologists in India, offering a potentially transformative approach to CAR T-cell therapy for cancer and autoimmune diseases. The research details a novel method of CAR T-cell therapy that could drastically reduce the cost and complexity of the treatment, making it far more accessible to patients in India where B-cell cancers and autoimmune disorders have high burden.
Traditional CAR T-cell therapy involves extracting a patient’s T-cells, genetically modifying them in a lab to target cancer cells, and then re-infusing them back into the body. The process is expensive, time-consuming, and requires specialized infrastructure. In India, the cost can range between ₹60-70 lakh (approximately $75,000 – $88,000 USD), putting it out of reach for many.
The new approach, developed by researchers from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases, Capstan Therapeutics, and the University of Pennsylvania, eliminates the need for external cell modification. Instead, the scientists use lipid nanoparticles (LNPs) – similar to those used in mRNA vaccines – to deliver genetic instructions directly into the patient’s T-cells, reprogramming them to fight the disease *inside* the body. The study found positive results in mice and monkeys, and found a significant depletion of B cells, without the need for chemotherapy or complex cell processing.
Dr. Vishwanath S., a senior consultant in medical oncology at Apollo Hospitals, Bengaluru, explains the potential impact: “Bypassing both complex *in vitro* manufacturing and chemotherapy-based lymphodepletion could make CAR T-cell therapies safer and more accessible for frail, elderly, and comorbid patients here in India.”
The study holds particular promise for India, where diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia are significant health concerns. The burden of autoimmune disorders is also rising. This new method would also eliminate some of the dangerous side effects that are caused by existing methods.
Anirban Mukhopadhyay, a geneticist and science communicator, noted that this new platform “could shift not just how we deliver CAR T-cell therapy but also who can benefit from it.”
While the results are promising, human trials are necessary to confirm the safety and efficacy of this new approach. Researchers, including Pankaj Prasad, caution that challenges remain, particularly in scaling up production and ensuring reproducibility. “Robust human trials will be essential to confirm safety, efficacy, and long-term outcomes”, said Dr. Vishwanath S.
If future trials are successful, this innovative approach could revolutionize immunotherapy and offer a more affordable and accessible treatment option for countless patients in India and worldwide.
First Piper 